The patient has a concurrent active malignancy other than treated non-melanoma skin cancers or in situ neoplasm; a patient with a prior history of malignancy is eligible, provided that they have been free of disease for >=  years
History of another primary invasive malignancy that has not been definitively treated or in remission for at least  years; patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses)
No other active malignancy within the past  years, except for non-melanoma skin cancers or carcinoma in situ of the cervix
Non-Melanoma skin cancers
Patients with other malignancies are ineligible for this study, other than non-melanoma skin cancers
Patients with second malignancy within  years of enrollment; patients curatively treated non-melanoma skin cancers or carcinoma in situ of the bladder, are not excluded
Other active non-melanoma metastatic cancers
No other active malignancies within the past  months (with the exception of nonmelanoma skin cancers or carcinoma in situ of the bladder) or life-threatening illnesses
Any known prior malignancy (not including non-melanoma skin cancers), unless treated with curative intent
Previous malignancy within  years other than non-melanomatous skin cancers or cancers of low malignant potential such as non-invasive urothelial carcinoma
Subjects must not have a history of a known secondary primary malignancy that is not in remission and/or that requires active therapy; exceptions include non-melanoma skin cancers and in situ cervical cancer that has undergone curative-intent local therapy
Patients with a history of another neoplasm, with the exception of non-metastatic, non-melanoma skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery or small field radiotherapy, within  years of registration will be excluded
Patients with another active malignancy that requires treatment excluding non-melanoma skin cancers
Patients with a second active malignancy, exceptions are localized non-melanoma skin cancers or prior in situ carcinoma
The subject has had evidence within  years of the start of study treatment of another malignancy which required systemic treatment (with the exception of nonmelanoma skin cancers or carcinoma in situ of the bladder)
History of another primary invasive malignancy that has not been definitively treated or in remission for at least  years; patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses)
History of another primary invasive malignancy unless definitively treated or in remission for at least  years; patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses)
Patients must not have other active malignancies other than non-melanoma skin cancers or superficial bladder cancer; subjects with a history of other cancers who have been adequately treated and have been recurrence-free for >=  years are eligible
Patients with other active malignancies are ineligible for this study, other than non-melanoma skin cancers
History of another primary invasive malignancy that has not been definitively treated or in remission for at least  years; patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses)
DONOR: Prior malignancies within the last  years except for non-melanoma skin cancers
Other known co-existing malignancies except non-melanoma skin cancer unless definitively treated and proven no evidence of recurrence for  years.
Prior malignancy, other than carcinoma in situ of the cervix and non-melanoma skin cancers, unless the prior malignancy was diagnosed and definitively treated >=  years previously, there is no subsequent evidence of recurrence, and the patient is considered by a physician to be at < % risk of relapse
Another diagnosis of malignancy within the  years preceding enrollment (excluding non-melanoma skin cancers or in situ cervical lesions, which are permitted)
No recent (within  years) or concurrent cancers other than non-melanoma skin cancers
No other active malignancies within the past  years (with the exception of nonmelanoma skin cancers, prostate cancer patients with stable biochemical recurrence/not on systemic therapy or carcinoma in situ of the bladder)
Other active malignancy (with the exception of locally treated non-melanoma skin cancers)
Matched Related Donor: Prior malignancy within the preceding five yrs, with the exception of non-melanoma skin cancers
Unrelated Donor: Prior malignancy within the preceding five yrs, with the exception of non-melanoma skin cancers
Diagnosis of another malignancy, with the exception of non-melanoma skin cancers within two years before the first dose, or previously treated for another malignancy with evidence of residual disease, with the exception of a synchronous endometrial cancer and non-melanoma skin cancers; carcinoma in situ will not be considered as malignancy
DONOR: Prior malignancy within the preceding  years, with the exception of non-melanoma skin cancers
Second malignancy other than non-melanoma skin cancers within the past  years
Other prior malignancies within  years, except non-melanoma skin cancers and synchronous ovarian primaries
No other active malignancies within the past  months (with the exception of nonmelanoma skin cancers or carcinoma in situ of the bladder) or life-threatening illnesses, in the opinion of the investigator
History of another primary invasive malignancy that has not been definitively treated or in remission for at least  years; patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses)
Previous malignancy with diagnosis or suspicion of recurrence within the past  years, not including non-melanoma skin cancers or in situ malignancies
Prior malignancy. Patients with nonmelanoma skin cancer or other cancers with greater than  years without evidence of disease recurrence are eligible
Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cancers
Patients must be disease-free from prior malignancies for >=  years, with the exception of non-melanoma skin cancers and superficial urothelial cancers
No other active malignancies within the past  months (with the exception of non-melanoma skin cancers or carcinoma in situ of the bladder) or life-threatening illnesses
Patients with second malignancy within  years of enrollment; patients curatively treated non-melanoma skin cancers or carcinoma in situ of the bladder, are not excluded
Without history of other cancers (excluding non-melanoma skin cancer)
Patients must not have other active malignancies other than non-melanoma skin cancers or carcinoma in situ of the bladder; subjects with a history of other cancers who have been adequately treated and have been recurrence-free for >=  years are eligible
Patients with an active second primary malignancy or history of malignancy within  years of enrollment are excluded, with the exception of non-melanoma skin cancers and cervical cancer which has been treated with curative therapy
History of malignancy other than non-melanoma skin cancers within  years prior to\r\nstudy enrollment
DONOR: Prior malignancy within the preceding five years, with the exception of non-melanoma skin cancers
Other active malignancies except cervical carcinomas in situ or clinically insignificant non-melanoma skin cancers
. History of another invasive malignancy in the last  years. Adequately treated noninvasive,non-melanoma skin cancers as well as in situ carcinoma of the cervix within the last  years will be allowed.
Patients with a history of another malignancy except for those who have been disease-free for  years; patients with a history of definitively treated non-melanoma skin cancer or squamous cell carcinoma of the cervix are eligible; patients with definitively treated in-situ cancers are eligible, regardless of timeframe
History of another primary invasive malignancy that has not been definitively treated or in remission for at least  years; patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses)
Treated, non-melanoma skin cancers
History of non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers treated by local excision or other cancers curatively treated with no evidence of disease for >=  years
Patients with other cancers (other than non-melanoma skin cancer) within the last five years
Patients with a, currently active, second malignancy other than non-melanoma skin cancers or non-invasive bladder cancers or other in-situ or non-invasive malignancies; patients who have completed therapy for a prior malignancy and are free of disease for >=  years are eligible
Patients with another primary cancer diagnosis within  years of consent, not including non-melanoma skin cancers
Active malignancy; exception: non-melanoma skin cancers cancer(s) for which diagnosis and treatment was completed >=  years prior to pre-registration
Any prior diagnosis of gastrointestinal cancer (including esophageal, small intestine, colon, pancreatic), or any diagnosis of other cancers (with the exception of non-melanoma skin) in which there has been any active treatment within the last three years
Other concurrent clinically active malignant disease, requiring treatment, with the exception of non-melanoma cancers of the skin or carcinoma in-situ of the cervix or non-metastatic prostate cancer.
Have received chemotherapy and/or radiation for any malignancy (excluding non-melanoma skin cancer and cancers confined to organs with removal as only treatment) in the past  years (preceding the time of registration)
For melanoma patients, if patients have a history of malignancy other than melanoma and other skin cancers in the past five years, their inclusion is up to the discretion of the physician
Presence of other active cancers; patients with stage I cancer who have received definitive local treatment within the last  years, and whom are considered unlikely to recur, are eligible; all patients with previously treated in-situ carcinoma (i.e., non-invasive) are eligible, as are patients with prior non-melanoma skin cancers
Patients must not have other concurrent malignancies (within the past  years with the exception of non-melanoma skin cancer and Rai stage  chronic lymphocytic leukemia), in situ carcinoma of any site, or life threatening illnesses, including untreated infection (must be at least  week off intravenous antibiotic therapy before beginning zolpidem)
Exclude any patient who has received treatment for cancer (excluding non-melanoma skin cancers) in the last  months
Patients must not have other concurrent malignancies (within the past  years with the exception of non-melanoma skin cancer and Rai stage  chronic lymphocytic leukemia), in situ carcinoma of any site, or life- threatening illnesses, including untreated infection (must be at least  week off intravenous antibiotic therapy before beginning enzalutamide)
